NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection

Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4–infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nannan, Hernandez, Dennis, Ueland, Joseph, Yang, Xiaoyan, Yu, Fei, Sims, Karen, Yin, Philip D., McPhee, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690147/
https://www.ncbi.nlm.nih.gov/pubmed/26170396
http://dx.doi.org/10.1093/infdis/jiv379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690147/
https://www.ncbi.nlm.nih.gov/pubmed/26170396
http://dx.doi.org/10.1093/infdis/jiv379

Ejemplares similares